for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Celsion Corporation

CLSN.OQ

Latest Trade

0.99USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.44

 - 

6.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.99
Open
--
Volume
--
3M AVG Volume
266.97
Today's High
--
Today's Low
--
52 Week High
6.50
52 Week Low
0.44
Shares Out (MIL)
86.56
Market Cap (MIL)
90.89
Forward P/E
-3.50
Dividend (Yield %)
--

Next Event

Q1 2021 Celsion Corp Earnings Release

Latest Developments

More

Celsion Corporation Receives FDA Fast Track Designation For Gen-1 In Advanced Ovarian Cancer

Celsion Corp - On Jan 27, 2021, Co Received A Notice From Nasdaq Listing Qualifications Department

Altium Capital Management Lp Reports Passive Stake Of 8.9% In Celsion Corp As Of Jan. 22 - SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Celsion Corporation

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Industry

Biotechnology & Drugs

Contact Info

997 Lenox Dr Ste 100

LAWRENCE TOWNSHIP, NJ

08648-2317

United States

+1.609.8969100

http://celsion.com/

Executive Leadership

Jeffrey Wayne Church

Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer

Khursheed Anwer

Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy

Nicholas Borys

Senior Vice President and Chief Medical Officer

Michael H. Tardugno

Executive Chairman of the Board, President, Chief Executive Officer

Donald P Braun

Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.270

2019

-0.770

2020

-0.670

2021(E)

-0.300
Price To Earnings (TTM)
--
Price To Sales (TTM)
181.77
Price To Book (MRQ)
2.30
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
27.14
LT Debt To Equity (MRQ)
21.14
Return on Investment (TTM)
-70.26
Return on Equity (TTM)
-56.68

Latest News

Latest News

BRIEF-Celsion Corporation Announces Pricing Of $10 Mln Underwritten Offering Of Common Stock

* ORATION ANNOUNCES PRICING OF $10 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK

BRIEF-Celsion Reports Data Safety Monitoring Board Recommendation To Proceed To Phase Ii Of The Ovation 2 Study In Advanced Ovarian Cancer

* CELSION REPORTS DATA SAFETY MONITORING BOARD RECOMMENDATION TO PROCEED TO PHASE II OF THE OVATION 2 STUDY IN ADVANCED OVARIAN CANCER

BRIEF-Celsion Reports Q1 Loss Per Share Of $0.20

* REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Celsion Reports That Sufficient Events Have Been Reached For Second Interim Analysis Of Phase III Optima Study Of Thermodox In Primary Liver Cancer

* CELSION REPORTS THAT SUFFICIENT EVENTS HAVE BEEN REACHED FOR THE SECOND INTERIM ANALYSIS OF THE PHASE III OPTIMA STUDY OF THERMODOX® IN PRIMARY LIVER CANCER

BRIEF-Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation From The European Medicines Agency

* CELSION’S GEN-1 IMMUNOTHERAPY RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY

BRIEF-Celsion Announces Highly Encouraging Initial Clinical Results From The Phase I Portion Of The Phase I/II Ovation 2 Study With Gen-1 In Patients With Advanced Ovarian Cancer

* CELSION ANNOUNCES HIGHLY ENCOURAGING INITIAL CLINICAL RESULTS FROM THE PHASE I PORTION OF THE PHASE I/II OVATION 2 STUDY WITH GEN-1 IN PATIENTS WITH ADVANCED OVARIAN CANCER Source text for Eikon: Further company coverage:

BRIEF-On March 5, Celsion Delivered Notice To Aspire Capital Fund, Terminating Common Stock Purchase Agreement Dated Oct 28, 2019 - SEC Filing

* CELSION - ON MARCH 5, CO DELIVERED NOTICE TO ASPIRE CAPITAL FUND, TERMINATING COMMON STOCK PURCHASE AGREEMENT DATED OCT 28, 2019 - SEC FILING Source: (http://bit.ly/2TPdbG7) Further company coverage:

BRIEF-Celsion CEO Issues Letter To Stockholders

* CELSION CORP - DO NOT EXPECT ANY INTERRUPTION IN OUR SUPPLY OF THERMODOX OR GEN-1 FROM MANUFACTURING PARTNERS IN CHINA

BRIEF-Celsion Corporation Prices $4.8 Million Registered Direct Offering

* CELSION CORPORATION PRICES $4.8 MILLION REGISTERED DIRECT OFFERING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up